Ladenburg Thalmann Financial Services’s Acceleron Pharma XLRN Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$57K	Buy	1,063 +269	+34%	+$12.3K	﹤0.01%	3444
2019 Q3	$32K	Buy	794 +116	+17%	+$5.03K	﹤0.01%	3742
2019 Q2	$29K	Hold	678	–	–	﹤0.01%	3838
2019 Q1	$32K	Buy	678 +100	+17%	+$4.39K	﹤0.01%	3716
2018 Q4	$26K	Buy	578 +443	+328%	+$22.1K	﹤0.01%	3719
2018 Q3	$8K	Sell	135 -2	-1%	-$98	﹤0.01%	4415
2018 Q2	$6K	Hold	137	–	–	﹤0.01%	4544
2018 Q1	$6K	Hold	137	–	–	﹤0.01%	4544
2017 Q4	$6K	Buy	137 +42	+44%	+$1.57K	﹤0.01%	4473
2017 Q3	$4K	Hold	95	–	–	﹤0.01%	4517
2017 Q2	$3K	Hold	95	–	–	﹤0.01%	4520
2017 Q1	$2K	Sell	95 -22	-19%	-$580	﹤0.01%	4618
2016 Q4	$4K	Buy	117 +4	+4%	+$127	﹤0.01%	4354
2016 Q3	$4K	Buy	113 +100	+769%	+$3.31K	﹤0.01%	4302
2016 Q2	$0	Hold	13	–	–	﹤0.01%	4883
2016 Q1	$0	Sell	13 -15	-54%	-$436	﹤0.01%	4860
2015 Q4	$1K	Buy	+28	New	+$1.01K	﹤0.01%	4579

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Ladenburg Thalmann Financial Services's XLRN Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Acceleron Pharma (XLRN) stake by 34% in Q4 2019, buying an estimated $12.3K and bringing the position to 1,063 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #3444.

Ladenburg Thalmann Financial Services first reported a position in XLRN in Q4 2015 and has held it in 17 quarters since. 183 funds tracked by Wall St. Rank hold XLRN as of Q4 2019.

Ladenburg Thalmann Financial Services held 1,063 shares of Acceleron Pharma worth $57K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 269 Acceleron Pharma shares in Q4 2019, an estimated $12.3K.
Acceleron Pharma made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3444 holding.
Ladenburg Thalmann Financial Services first reported a position in Acceleron Pharma in Q4 2015 and has held it in 17 quarters since.
183 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.